New Blood Pool Contrast Agent - Ablavar

......................................................................................................

There have been quite a number of discussions recently on "Ablavar" - the newly FDA-approved blood pool contrast agent for use in magnetic resonance angiography (MRA) to evaluate aortoilac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD). Is anyone out there who has experience in the clinical use of Ablavar willing to share with us the safety and efficacy of this blood pool contrast agent? MRA images using Ablavar, if available, will be awesome and most welcome. The images can be sent to me through email and I'll post them up here for sharing.

Illustrated below is one of the clinical examples of the applicaton of blood pool contrast agent from www.bloodpoolagents.com:

(Click on image to enlarge)

More information on Blood Pool Agents.

Tags: Ablavar, Gadofosveset trisodium, Gd, MRA, AIOD, PVD, blood pool contrast agent, aneurysm spurium, thrombosis

Reference:
Goyen M et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.Radiology. 2005;236(3):825-833.

Rapp JH et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71-78.

Perreault P et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.Radiology. 2003;229(3):811-820.